Related Experiment Video
Updated: Jun 4, 2026

Identification and Analysis of Mouse Erythroid Progenitors using the CD71/TER119 Flow-cytometric Assay
Published on: August 5, 2011
Candidate biomarkers for erythropoietin response in end-stage renal disease
1Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, Michigan 48202, USA. Abesara1@hfhs.org
Abstract:
Hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) is important clinically and economically. Escalation of dose may produce harm. Post hoc analyses of clinical trials showed that responsiveness could be predicted by hemoglobin response to a fixed dose escalation. This maneuver requires weeks to months. The study by Merchant et al. offers promise that peptidomic analyses of patient sera and mass spectrometry can identify biomarkers of both responsiveness and resistance to ESAs.
Related Concept Videos
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Serum Studies: Renal Function Tests
Kidney Transplant I: Introduction
Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate
Chronic Kidney Disease III: Interprofessional Care